Lenacapavir (Sunlenca®) is now included in the list of HIV therapies. Lenacapavir is a multistage, selective inhibitor of HIV-1 capsid function that directly binds to the interface between capsid protein (CA) subunits. Initiation of treatment with lenacapavir requires tablets to be taken as oral loading prior to administration of a long-acting sub-cutaneous injection which is then administered every 6 months.
Lenacapavir is indicated in the European Union for the treatment of adults with multi-drug resistant HIV infection in combination with other antiretroviral(s), for whom it is otherwise not possible to construct a suppressive anti-viral regimen. A New Drug Application (NDA) has been submitted to the U.S. Food & Drug Administration (FDA) and is currently being considered.